Velimogene aliplasmid

N/A

Report date: 2024/05/17 20:00:39

Base Information

Drug NameVelimogene aliplasmid
Drug Alias NameAllovectinAllovectin-7VCL-1005-208VCL-1005
ClassificationBiologics
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsSkin NeoplasmsHead and Neck NeoplasmsCarcinoma, Squamous Cell +[4
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[14
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesFresh Tracks Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesVical Incorporated
Active IndicationsN/A
Inactive IndicationsSkin NeoplasmsHead and Neck NeoplasmsCarcinoma, Squamous Cell +[4

Other Information

ATC CodeN/A
Related LinksN/A